Effect of pioglitazone on menstrual cyclicity

Effect of pioglitazone on menstrual cyclicity in young non obese women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012072810415N1

Enrollment

Registered

2012-11-15

Start date

2012-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

pioglitazone , Tablet 30mg, once daily.

Treatment - Drugs

pioglitazone , Tablet 30mg, once daily

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: More than 12 ovarian follicles with the diameter >mm 2-9; oligomenorrhea (menstrual cycle more than 35 days);amenorrhea (no menstrual cycle for 3 months);non obese women with Body Mass Index=18.5-24.99 Exclusion Criteria: hyperprolactinemia; thyroid abnormalities; cushing syndrome; adrenal heperplasia.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Menstrual cyclicity. Timepoint: six months following start of treatment. Method of measurement: visual scale of menstrual cyclicity.	—

Secondary

Measure	Time frame
Weight. Timepoint: 6 month after start of treatment. Method of measurement: scale measuring.;Body Mass Index. Timepoint: 6 month after start of treatment. Method of measurement: weight (kg)/[ height (m)]2.;Serum LH. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Serum testostrone. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Fasting Blood Sugar. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Fasting insulin. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Serum total cholestrol. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Serum tr. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.	—

Measure

Time frame

Weight. Timepoint: 6 month after start of treatment. Method of measurement: scale measuring.;Body Mass Index. Timepoint: 6 month after start of treatment. Method of measurement: weight (kg)/[ height (m)]2.;Serum LH. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Serum testostrone. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Fasting Blood Sugar. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Fasting insulin. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Serum total cholestrol. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.;Serum tr. Timepoint: 6 month after start of treatment. Method of measurement: laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRazieh Firouzabadi

Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences

dr_firouzabadi@ssu.ac.ir+98 35 1824 8122

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026